|
|
|
| Correlation Studies of Programmed Death Ligand 1 and EGFR Gene Mutations in Non-Small Cell Lung Carcinoma |
| YAN Limin, LI Xuemei, LEI Chong, et al |
| Hebei Tangshan Gongren Hospital, Hebei Tangshan 063000, China |
|
|
|
|
Abstract Objective: To find out the reason for poor immunotherapy effect of epidermal growth factor receptor (EGFR) mutant non small cell lung carcinoma (NSCLC) by analyzing the correlation between programmed cell death-ligand 1 (PD-L1) expression and EGFR gene mutation status, and to provide reference for precise diagnosis and treatment of EGFR-mutant NSCLC patients.Methods: A total of 308 NSCLC patients who underwent EGFR gene detection and PD-L1 immunohistochemical staining at the same time in the Department of Pathology of Tangshan Gongren Hospital from 2020 to 2021 were collected. The relationship between PD-L1 expression intensity and EGFR gene mutation rate, and the correlation between EGFR mutation status and PD-L1 expression intensity, were analyzed. Results: EGFR mutation rates were 71.30%, 57.55%, 50.00% and 44.12% (P=0.017, r=-0.176) in PD-L1 negative, weakly positive, moderately positive and strongly positive patients, respectively. The low and high expression rates of PD-L1 were 74.19% and 25.81% in the EGFR mutant NSCLC, and 62.30% and 37.70% in the wild type (P=0.027). Conclusion: There is a negative correlation between the expression intensity of PD-L1 and EGFR mutation rate. The higher the expression of PD-L1, the lower the mutation rate of EGFR. Patients with EGFR mutant NSCLC were more likely to have low expression of PD-L1.
|
|
|
|
|
|
[1] 肿瘤医学论坛.2020年全球癌症最新数据解读[J].中国肿瘤临床与康复,2021,28(3):301.
[2] 吴志美,喻海忠,桑玉玉.非小细胞肺癌根治术后EGFR基因突变状态对EGFR-TKI靶向治疗效果的影响[J].国际检验医学杂志,2020,41(20):2489-2493,2497.
[3] Lisberg A,Jcummings A,Goldman JW,et al.A phase II study of Pembro1izumab in EGFR mutant,PD-Ll+,tyrosine kinase inhibitor naive patients with advanced NSCLC[J].Thorac Oncol,2018,13(8):1138-1145.
[4] Ahn MJ,Sun JM,Lee SH,etal.EGFR TKI combination with immunotherapy in non small cell 1ung cancer[J].Expert Opin Drug Saf,2017,16(4): 465-469.
[5] Takada K,Toyokawa G,Tagawa T,et al.PD-L1 expression according to the EGFR status in primary lung adenocarcinoma[J].Lung Cancer,2018,116: 1-6.
[6] Azuma K,Ota K,Kawahara A,et al.Association of PD-L1 over expression with activating EGFR mutations in surgically resected non small cell lung cancer[J].Ann Oncol,2014,25(10): 1935-1940.
[7] Ota K,Azuma K,Kawahara AJ,et al.Induction of PD-L1 exression by the EML4-ALK oncoprotein and downstream signaling pathways in non small cel1 lung cancer[J].Clin cancer Res,2015,21(17): 4014-4021.
[8] Song ZJ,Yu XJ,Cheng G,et al.Programmed death-1igand 1 expression associated with mo1ecular characteristics in surgically resected lung adenocarcinoma[J].Transl Med,2016,14(1): 188. |
|
|
|
2022, Vol. 28 
